- Home
- GXAI vs VRAX Comparison
GXAI vs VRAX Comparison
Compare GXAI & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GXAI
- VRAX
- Stock Information
- Founded
- GXAI 2021
- VRAX 2013
- Country
- GXAI United States
- VRAX United Kingdom
- Employees
- GXAI N/A
- VRAX N/A
- Industry
- GXAI
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- GXAI
- VRAX Health Care
- Exchange
- GXAI Nasdaq
- VRAX Nasdaq
- Market Cap
- GXAI 8.0M
- VRAX 7.3M
- IPO Year
- GXAI 2023
- VRAX 2022
- Fundamental
- Price
- GXAI $1.18
- VRAX $1.29
- Analyst Decision
- GXAI
- VRAX
- Analyst Count
- GXAI 0
- VRAX 0
- Target Price
- GXAI N/A
- VRAX N/A
- AVG Volume (30 Days)
- GXAI 744.9K
- VRAX 194.7K
- Earning Date
- GXAI 03-26-2025
- VRAX 02-05-2025
- Dividend Yield
- GXAI N/A
- VRAX N/A
- EPS Growth
- GXAI N/A
- VRAX N/A
- EPS
- GXAI N/A
- VRAX N/A
- Revenue
- GXAI $2,979.00
- VRAX $84,872.00
- Revenue This Year
- GXAI N/A
- VRAX $5,169.18
- Revenue Next Year
- GXAI N/A
- VRAX $66.97
- P/E Ratio
- GXAI N/A
- VRAX N/A
- Revenue Growth
- GXAI N/A
- VRAX 7.03
- 52 Week Low
- GXAI $1.01
- VRAX $0.60
- 52 Week High
- GXAI $9.74
- VRAX $9.00
- Technical
- Relative Strength Index (RSI)
- GXAI 40.91
- VRAX 33.99
- Support Level
- GXAI $1.04
- VRAX $1.22
- Resistance Level
- GXAI $1.24
- VRAX $1.84
- Average True Range (ATR)
- GXAI 0.13
- VRAX 0.18
- MACD
- GXAI 0.02
- VRAX -0.02
- Stochastic Oscillator
- GXAI 35.18
- VRAX 9.59
About GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.